MedTrace Logo

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

NCT06156683 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2024-08-01

No results posted yet for this study

Summary

The study is an observational retrospective cohort study using longitudinal secondary data. Pregnant women with MS are assessed for exposure to Kesimpta and other MS disease modifying drugs (MSDMD) and followed up for adverse pregnancy and infant outcomes.

Conditions

Interventions

OTHER

Multiple sclerosis disease modifying drug

There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2028-02-01
Completion
2028-02-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06156683 on ClinicalTrials.gov